Inhibrx Biosciences Inc

INBX displayed a Bearish Exhaustion candle at a key support area, signaling a potential bottoming bounce into the 50-day SMA and 200-day SMA zone. While medium-term bias remains bullish under the higher-highs higher-lows regime and exhaustion signal, price currently sits below the 9- and 20-period EMAs and requires a clearer acceptance of the support zone. Execution will be deferred until pullbacks into this structural support are reliably held.

• ↑FDA accepted ozekibart BLA for oncology; review set April 14, 2027.
• ↑$325 M debt facility (Oxford Finance) with $100 M funded in July for R&D.
• ↓Q2 2026 net loss $36.7 M ($2.34/share) underscores weak profitability.